Change search
ReferencesLink to record
Permanent link

Direct link
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.
Show others and affiliations
2008 (English)In: Lancet, ISSN 1474-547X, Vol. 372, no 9633, 145-54 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
2008. Vol. 372, no 9633, 145-54 p.
Keyword [en]
Adult, Aged, Aged; 80 and over, Cancer Vaccines/adverse effects/*therapeutic use, Disease-Free Survival, Female, Heat-Shock Proteins/adverse effects/*therapeutic use, Humans, Kidney Neoplasms/pathology/*prevention & control/surgery, Male, Middle Aged, Neoplasm Recurrence; Local/*prevention & control, Observation, Postoperative Period, Risk Factors
URN: urn:nbn:se:umu:diva-10348PubMedID: 18602688OAI: diva2:150019
Available from: 2008-08-15 Created: 2008-08-15 Last updated: 2011-01-10Bibliographically approved

Open Access in DiVA

No full text

Other links


Search in DiVA

By author/editor
Ljungberg, Börje
By organisation
Urology and Andrology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 27 hits
ReferencesLink to record
Permanent link

Direct link